[PDF] Top 20 Rev. Bras. Hematol. Hemoter. vol.33 número6
Has 10000 "Rev. Bras. Hematol. Hemoter. vol.33 número6" found on our website. Below are the top 20 most common "Rev. Bras. Hematol. Hemoter. vol.33 número6".
Rev. Bras. Hematol. Hemoter. vol.33 número6
... So the RBHH started to be printed in English, and because of this it was indexed in PubMed Central (PMC) of the National Institutes of Health, an auspicious achievement in 2011. Volume 33 will be indexed in PMC in ... See full document
1
Rev. Bras. Hematol. Hemoter. vol.33 número6
... Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.. Comm[r] ... See full document
6
Rev. Bras. Hematol. Hemoter. vol.33 número6
... in 494 Spanish patients with refractory or recurrent HL, 40.5% had B symptoms and 33% had bulky disease. These numbers contrast with the 71% of patients with B symptoms and the 40% of patients with bulky disease ... See full document
7
Rev. Bras. Hematol. Hemoter. vol.33 número6
... The following table replaces the Table incorrectly published in the Original Article “Reticulocytes indices in ß thalassemia trait individuals” published in Volume 33 Issue nº 5 of the [r] ... See full document
1
Rev. Bras. Hematol. Hemoter. vol.33 número6
... Figure 2 – Bone marrow cytomorphological changes in patients co-infected with visceral leishmaniasis and human immunodeficiency virus on Leishman stain (magnification: 1000x) (A) multip[r] ... See full document
1
Rev. Bras. Hematol. Hemoter. vol.33 número6
... beta-thalassemia subjects and in individuals without Hb alterations, to estimate the polymorphism frequency related with beta thalassemia mutations and to correlate the2. presence of the[r] ... See full document
1
Rev. Bras. Hematol. Hemoter. vol.33 número6
... For home medication, oral antibiotics (1 tablet of 500-mg cephalexin every 6 hours) and an antifibrinolytic medication (2 tablets of 250-mg tranexamic acid every 8 hours) were prescribed[r] ... See full document
2
Rev. Bras. Hematol. Hemoter. vol.33 número6
... Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Liso V, Specchia G, Pogliani EM, Palumbo G, Mininni D, Rossi V, et al[r] ... See full document
3
Rev. Bras. Hematol. Hemoter. vol.33 número6
... As thymoma-associated hematological dyscrasias, which include pure red cell aplasia, aplastic anemia and myasthenia gravis, are supposed to be of immunologic origin, two cases of very se[r] ... See full document
2
Rev. Bras. Hematol. Hemoter. vol.33 número6
... 33. Chaytan C, Schwenk MH, Al-saloum MM, Spinowitz BS.. Safety of iron sucrose in hemodialysis patients intolerant to other parenteral iron products. Nephron Clin Pract. 2004;96(2):c63-6 34. Van Wyck DB, Roppolo ... See full document
9
Rev. Bras. Hematol. Hemoter. vol.33 número6
... 25. Mahon FX, Réa D, Guilhot J, Guilhot F, Huguet F, Nicolini F, Legros L, Charbonnier A, Guerci A, Varet B, Etienne G, Reiffers J, Rousselot P; Intergroupe Français des Leucémies Myéloïdes Chroniques. Intergroupe ... See full document
6
Rev. Bras. Hematol. Hemoter. vol.33 número6
... for all people is emphasized and to gradually evaluate the various models of access to high-cost treatments and the possibility of cooperation between Latin American centers to stimulate[r] ... See full document
6
Rev. Bras. Hematol. Hemoter. vol.33 número6
... The O blood group phenotype of the ABO histo-blood group system is associated with allergic rhinitis in male but not in female patients.. Acknowledgments.[r] ... See full document
5
Rev. Bras. Hematol. Hemoter. vol.33 número6
... Methods: Eighty-six adult patients with iron deficiency anemia, who had intolerance or showed no effect with oral iron therapy, received a weekly dose of 200 mg of intravenous iron sucr[r] ... See full document
5
Rev. Bras. Hematol. Hemoter. vol.33 número6
... The myelodysplastic syndromes (MDS), acute myeloid leukemias (AML) and secondary myeloproliferative syndromes (MPS) constitute a group of myeloid neoplasias (MNs) which result from expos[r] ... See full document
7
Rev. Bras. Hematol. Hemoter. vol.33 número6
... Jesús M Hernández-Rivas Secondary myeloid neoplasias are a heterogeneous group of diseases characterized by the proliferation of myeloid cells; they were recently recognized by the World[r] ... See full document
2
Rev. Bras. Hematol. Hemoter. vol.33 número6
... Jesús M Hernández-Rivas Secondary myeloid neoplasias are a heterogeneous group of diseases characterized by the proliferation of myeloid cells; they were recently recognized by the World[r] ... See full document
10
Rev. Bras. Hematol. Hemoter. vol.33 número6
... Stimulation using granulocyte growth factors associated or not to chemotherapy, is broadly used as a method in the mobilization of hematopoietic progenitor cells (HPC) from bone marrow o[r] ... See full document
7
Rev. Bras. Hematol. Hemoter. vol.33 número6
... write about cytogenetics, in particular, the JAK2 and MPL mutations in polycythemia vera, primary myelofibrosis and essential thrombocythemia.. (1).[r] ... See full document
2
Rev. Bras. Hematol. Hemoter. vol.33 número6
... They evaluated the efficacy and safety of IV iron sucrose (IS, 200 mg/week, until anemia correction or replenishment of calculated ID; 515 infusions) for the treatment of 86 adult patien[r] ... See full document
3
temas relacionados